Novartis Declares Cosentyx FDA Approval for Pediatric Patients: The First IL-17A Inhibitor to Transform Hidradenitis Suppurativa Treatment
osentyx FDA approval marks first IL-17A inhibitor for pediatric patients 12+ with hidradenitis suppurativa. Discover how this breakthrough treatment transforms care for adolescents facing HS.
